Last 12 months
Inside the activity.
0 purchase rows · 54 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 5 |
| May 2026 | 0 | 12 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2017 Filed May 12, 2017 23:24 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 44,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009632 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,258.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (25,300) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (25,300) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:12 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionPerformance Rights · Derivative | 10,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009629 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,850 shares Expires 2017-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:12 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Tax withholdingCommon Stock | 5,662 | $110.58 | $626,103.96 |
DisclosureSEC source: 0001225208-17-009629 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,282.6555 F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:12 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionCommon Stock | 10,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009629 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,944.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,200) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:11 UTC |
Verguet Patrick BCVP, Europe
|
Exercise / conversionPerformance Rights · Derivative | 9,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009628 · doc4.xml · derivative · entry 3 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,625 shares Expires 2017-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:11 UTC |
Verguet Patrick BCVP, Europe
|
Tax withholdingCommon Stock | 494 | $110.58 | $54,626.52 |
DisclosureSEC source: 0001225208-17-009628 · doc4.xml · nonDerivative · entry 2 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,268.1496 F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:11 UTC |
Verguet Patrick BCVP, Europe
|
Exercise / conversionCommon Stock | 9,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009628 · doc4.xml · nonDerivative · entry 1 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,762.1496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:11 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
Exercise / conversionPerformance Rights · Derivative | 6,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009627 · doc4.xml · derivative · entry 3 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,037 shares Expires 2017-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F3 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:11 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
Tax withholdingCommon Stock | 2,478 | $110.58 | $274,017.24 |
DisclosureSEC source: 0001225208-17-009627 · doc4.xml · nonDerivative · entry 2 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,491.0375 F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:11 UTC |
WANG HUIMINCVP, Japan & Intercontinental
|
Exercise / conversionCommon Stock | 6,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009627 · doc4.xml · nonDerivative · entry 1 WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,969.0375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (3,450) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| May 08, 2017 Filed May 10, 2017 01:19 UTC |
SELLERS ROBERT W.A.VP, Corporate Controller
|
Tax withholdingCommon Stock | 311 | $110.58 | $34,390.38 |
DisclosureSEC source: 0001225208-17-009438 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,629.3757 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 08, 2017 Filed May 9, 2017 23:07 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 9,100 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-009436 · doc4.xml · derivative · entry 8 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,300 Underlying: Common Stock · 9,100 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 08, 2017 Filed May 9, 2017 23:07 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
SaleCommon Stock | 9,100 | $110.17 | $1,002,514.24 |
DisclosureSEC source: 0001225208-17-009436 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,094.6555 F3 · price: This transaction was executed in multiple trades at prices ranging from $110.00 to $110.79. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 08, 2017 Filed May 9, 2017 23:07 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionCommon Stock | 9,100 | $44.62 | $405,996.50 |
DisclosureSEC source: 0001225208-17-009436 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,194.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 05, 2017 Filed May 9, 2017 23:07 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 10,000 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-009436 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,400 Underlying: Common Stock · 10,000 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 05, 2017 Filed May 9, 2017 23:07 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
SaleCommon Stock | 10,000 | $110.50 | $1,104,997.00 |
DisclosureSEC source: 0001225208-17-009436 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,094.6555 F2 · price: This transaction was executed in multiple trades at prices ranging from $110.02 to $110.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 05, 2017 Filed May 9, 2017 23:07 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionCommon Stock | 10,000 | $44.62 | $446,150.00 |
DisclosureSEC source: 0001225208-17-009436 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,094.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 04, 2017 Filed May 4, 2017 23:59 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 10,000 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · derivative · entry 14 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,400 Underlying: Common Stock · 10,000 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 04, 2017 Filed May 4, 2017 23:59 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
SaleCommon Stock | 10,000 | $110.27 | $1,102,681.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 8 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,094.6555 F6 · price: This transaction was executed in multiple trades at prices ranging from $110.60 to $110.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 04, 2017 Filed May 4, 2017 23:59 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionCommon Stock | 10,000 | $44.62 | $446,150.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,094.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:59 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 18,720 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · derivative · entry 13 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,720 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:59 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 400 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · derivative · entry 12 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,400 Underlying: Common Stock · 400 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:59 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
SaleCommon Stock | 13,720 | $109.72 | $1,505,400.93 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,094.6555 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F5 · price: This transaction was executed in multiple trades at prices ranging from $109.28 to $110.15. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:59 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
SaleCommon Stock | 400 | $110.10 | $44,039.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,814.6555 F4 · price: This transaction was executed in multiple trades at prices ranging from $110.03 to $110.15. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:59 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionCommon Stock | 400 | $44.62 | $17,846.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,214.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:59 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionCommon Stock | 18,720 | $25.48 | $476,985.60 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,814.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:25 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 48,900 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-009193 · doc4.xml · derivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,900 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:25 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 200 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-009193 · doc4.xml · derivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,200 Underlying: Common Stock · 200 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:25 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 48,800 | $109.71 | $5,353,740.64 |
DisclosureSEC source: 0001225208-17-009193 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,983.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $109.19 to $110.15. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:25 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 300 | $110.20 | $33,060.00 |
DisclosureSEC source: 0001225208-17-009193 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,783.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:25 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 200 | $44.62 | $8,923.00 |
DisclosureSEC source: 0001225208-17-009193 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,083.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 03, 2017 Filed May 4, 2017 23:25 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 48,900 | $25.48 | $1,245,972.00 |
DisclosureSEC source: 0001225208-17-009193 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,883.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 02, 2017 Filed May 4, 2017 23:59 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 10,000 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · derivative · entry 11 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,800 Underlying: Common Stock · 10,000 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 02, 2017 Filed May 4, 2017 23:59 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
SaleCommon Stock | 10,000 | $110.05 | $1,100,540.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,094.6555 F2 · price: This transaction was executed in multiple trades at prices ranging from $110.00 to $110.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 02, 2017 Filed May 4, 2017 23:59 UTC |
BOBO DONALD E JRCVP, Heart Valve Therapy
|
Exercise / conversionCommon Stock | 10,000 | $44.62 | $446,150.00 |
DisclosureSEC source: 0001225208-17-009195 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,094.6555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 28, 2017 Filed May 2, 2017 00:36 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 49,100 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-008740 · doc4.xml · derivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,900 Underlying: Common Stock · 49,100 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 28, 2017 Filed May 2, 2017 00:36 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 37,200 | $109.61 | $4,077,439.92 |
DisclosureSEC source: 0001225208-17-008740 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,983.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $108.91 to $109.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 28, 2017 Filed May 2, 2017 00:36 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 11,900 | $110.32 | $1,312,755.64 |
DisclosureSEC source: 0001225208-17-008740 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,183.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $109.91 to $110.84. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 28, 2017 Filed May 2, 2017 00:36 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 49,100 | $25.48 | $1,251,068.00 |
DisclosureSEC source: 0001225208-17-008740 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,083.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:11 UTC |
SELLERS ROBERT W.A.VP, Corporate Controller
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 12,960 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-008605 · doc4.xml · derivative · entry 3 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,960 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:11 UTC |
SELLERS ROBERT W.A.VP, Corporate Controller
|
SaleCommon Stock | 12,960 | $109.50 | $1,419,120.00 |
DisclosureSEC source: 0001225208-17-008605 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,940.3757 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:11 UTC |
SELLERS ROBERT W.A.VP, Corporate Controller
|
Exercise / conversionCommon Stock | 12,960 | $25.48 | $330,220.80 |
DisclosureSEC source: 0001225208-17-008605 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,900.3757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC |
Verguet Patrick BCVP, Europe
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 24,000 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-008604 · doc4.xml · derivative · entry 5 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F6 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC |
Verguet Patrick BCVP, Europe
|
SaleCommon Stock | 9,659 | $109.33 | $1,055,987.56 |
DisclosureSEC source: 0001225208-17-008604 · doc4.xml · nonDerivative · entry 4 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,137.1496 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F5 · price: This transaction was executed in multiple trades at prices ranging from $108.83 to $109.82. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC |
Verguet Patrick BCVP, Europe
|
SaleCommon Stock | 7,636 | $110.08 | $840,580.04 |
DisclosureSEC source: 0001225208-17-008604 · doc4.xml · nonDerivative · entry 3 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,796.1496 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $109.89 to $110.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC |
Verguet Patrick BCVP, Europe
|
SaleCommon Stock | 6,705 | $108.36 | $726,522.96 |
DisclosureSEC source: 0001225208-17-008604 · doc4.xml · nonDerivative · entry 2 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,432.1496 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $107.83 to $108.82. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC |
Verguet Patrick BCVP, Europe
|
Exercise / conversionCommon Stock | 24,000 | $25.48 | $611,520.00 |
DisclosureSEC source: 0001225208-17-008604 · doc4.xml · nonDerivative · entry 1 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,137.1496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC |
Zovighian Bernard JCVP, Surgical Heart Valves
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 20,000 | $0.00 Strike: $66.86 | $0.00 |
DisclosureSEC source: 0001225208-17-008603 · doc4.xml · derivative · entry 3 Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,556 Underlying: Common Stock · 20,000 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC |
Zovighian Bernard JCVP, Surgical Heart Valves
|
SaleCommon Stock | 18,050 | $109.21 | $1,971,318.12 |
DisclosureSEC source: 0001225208-17-008603 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,552.4816 F2 · price: This transaction was executed in multiple trades at prices ranging from $109.21 to $109.7550. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC |
Zovighian Bernard JCVP, Surgical Heart Valves
|
Exercise / conversionCommon Stock | 20,000 | $66.86 | $1,337,200.00 |
DisclosureSEC source: 0001225208-17-008603 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,602.4816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.